143 related articles for article (PubMed ID: 23091890)
41. Expression of phosphorylated p27(Kip1) protein and Jun activation domain-binding protein 1 in human pituitary tumors.
Korbonits M; Chahal HS; Kaltsas G; Jordan S; Urmanova Y; Khalimova Z; Harris PE; Farrell WE; Claret FX; Grossman AB
J Clin Endocrinol Metab; 2002 Jun; 87(6):2635-43. PubMed ID: 12050228
[TBL] [Abstract][Full Text] [Related]
42. Overexpression of p21WAF1/CIP1 and MDM2 characterizes serous borderline ovarian tumors.
Palazzo JP; Monzon F; Burke M; Hyslop T; Dunton C; Barusevicius A; Capuzzi D; Kovatich AJ
Hum Pathol; 2000 Jun; 31(6):698-704. PubMed ID: 10872663
[TBL] [Abstract][Full Text] [Related]
43. Jab1 Silencing Inhibits Proliferation and Sensitizes to Cisplatin in Biliary Tract Cancer.
Nam AR; Kim JW; Park JE; Bang JH; Jin MH; Oh DY; Bang YJ
Cancer Res Treat; 2019 Jul; 51(3):886-900. PubMed ID: 30282449
[TBL] [Abstract][Full Text] [Related]
44. Cannabinoid receptor type 1 immunoreactivity and disease severity in human epithelial ovarian tumors.
Messalli EM; Grauso F; Luise R; Angelini A; Rossiello R
Am J Obstet Gynecol; 2014 Sep; 211(3):234.e1-6. PubMed ID: 24721263
[TBL] [Abstract][Full Text] [Related]
45. Hepatitis B virus pre-S2 mutant surface antigen induces degradation of cyclin-dependent kinase inhibitor p27Kip1 through c-Jun activation domain-binding protein 1.
Hsieh YH; Su IJ; Wang HC; Tsai JH; Huang YJ; Chang WW; Lai MD; Lei HY; Huang W
Mol Cancer Res; 2007 Oct; 5(10):1063-72. PubMed ID: 17951406
[TBL] [Abstract][Full Text] [Related]
46. Jab1 as a mediator of nuclear export and cytoplasmic degradation of p53.
Lee EW; Oh W; Song J
Mol Cells; 2006 Oct; 22(2):133-40. PubMed ID: 17085963
[TBL] [Abstract][Full Text] [Related]
47. Overexpression of Jun activation domain-binding protein 1 in nonsmall cell lung cancer and its significance in p27 expression and clinical features.
Osoegawa A; Yoshino I; Kometani T; Yamaguchi M; Kameyama T; Yohena T; Maehara Y
Cancer; 2006 Jul; 107(1):154-61. PubMed ID: 16721818
[TBL] [Abstract][Full Text] [Related]
48. [Incidence of proapoptotic proteins p53 and p21 in epithelial ovarian tumors].
Gajewska M; Wielgoś M; Panek G; Marczewska J
Ginekol Pol; 2014 Feb; 85(2):111-6. PubMed ID: 24745156
[TBL] [Abstract][Full Text] [Related]
49. Expression and correlation of Lewis y antigen and TGF-β1 in ovarian epithelial carcinoma.
Wang ST; Liu JJ; Wang CZ; Lin B; Hao YY; Wang YF; Gao S; Qi Y; Zhang SL; Iwamori M
Oncol Rep; 2012 Apr; 27(4):1065-71. PubMed ID: 22138668
[TBL] [Abstract][Full Text] [Related]
50. Comparison of plasma amino acid profile-based index and CA125 in the diagnosis of epithelial ovarian cancers and borderline malignant tumors.
Miyagi E; Maruyama Y; Mogami T; Numazaki R; Ikeda A; Yamamoto H; Hirahara F
Int J Clin Oncol; 2017 Feb; 22(1):118-125. PubMed ID: 27623814
[TBL] [Abstract][Full Text] [Related]
51. Immunohistochemical analysis of bcl-2, bax, mcl-1, and bcl-X expression in ovarian surface epithelial tumors.
Wehrli BM; Krajewski S; Gascoyne RD; Reed JC; Gilks CB
Int J Gynecol Pathol; 1998 Jul; 17(3):255-60. PubMed ID: 9656122
[TBL] [Abstract][Full Text] [Related]
52. Prognostic and predictive values of Nrf2, Keap1, p16 and E-cadherin expression in ovarian epithelial carcinoma.
Liew PL; Hsu CS; Liu WM; Lee YC; Lee YC; Chen CL
Int J Clin Exp Pathol; 2015; 8(5):5642-9. PubMed ID: 26191276
[TBL] [Abstract][Full Text] [Related]
53. The Relevance of Women's Diseases, Jun Activation-domain Binding Protein 1 (JAB1) and p27(kip1).
Kim M; Kim TH; Lee HH
J Menopausal Med; 2016 Apr; 22(1):6-8. PubMed ID: 27152307
[TBL] [Abstract][Full Text] [Related]
54. Immunohistochemical study of Skp2 and Jab1, two key molecules in the degradation of P27, in lung adenocarcinoma.
Goto A; Niki T; Moriyama S; Funata N; Moriyama H; Nishimura Y; Tsuchida R; Kato JY; Fukayama M
Pathol Int; 2004 Sep; 54(9):675-81. PubMed ID: 15363035
[TBL] [Abstract][Full Text] [Related]
55. [Expression of p21(WAF1) and its relationship with p53 and PCNA protein in epithelial ovarian cancer].
Yan XJ; Liang LZ; Li DC; Li JL; Zhang CQ; Yuan SH
Ai Zheng; 2004 Jan; 23(1):74-80. PubMed ID: 14720380
[TBL] [Abstract][Full Text] [Related]
56. Immunohistochemical detection of p53 protein in borderline and malignant serous ovarian tumors.
Klemi PJ; Takahashi S; Joensuu H; Kiilholma P; Narimatsu E; Mori M
Int J Gynecol Pathol; 1994 Jul; 13(3):228-33. PubMed ID: 7928055
[TBL] [Abstract][Full Text] [Related]
57. Interaction and colocalization of PGP9.5 with JAB1 and p27(Kip1).
Caballero OL; Resto V; Patturajan M; Meerzaman D; Guo MZ; Engles J; Yochem R; Ratovitski E; Sidransky D; Jen J
Oncogene; 2002 May; 21(19):3003-10. PubMed ID: 12082530
[TBL] [Abstract][Full Text] [Related]
58. Quantification of p53 in epithelial ovarian cancer.
Geisler JP; Geisler HE; Wiemann MC; Givens SS; Zhou Z; Miller GA
Gynecol Oncol; 1997 Sep; 66(3):435-8. PubMed ID: 9299258
[TBL] [Abstract][Full Text] [Related]
59. Skp2 and Jab1 expression are associated with inverse expression of p27(KIP1) and poor prognosis in oral squamous cell carcinomas.
Shintani S; Li C; Mihara M; Hino S; Nakashiro K; Hamakawa H
Oncology; 2003; 65(4):355-62. PubMed ID: 14707456
[TBL] [Abstract][Full Text] [Related]
60. Huntingtin with an expanded polyglutamine repeat affects the Jab1-p27(Kip1) pathway.
Cong SY; Pepers BA; Zhou TT; Kerkdijk H; Roos RA; van Ommen GJ; Dorsman JC
Neurobiol Dis; 2012 Jun; 46(3):673-81. PubMed ID: 22426400
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
